JE MIN YOO, PhD

Dr. Yoo serves as a Chief Technology Officer at BioGraphene US office.

During his graduate course, he observed the possible connection between GQDs and the abnormal aggregation/fibrillation of alpha-synuclein, which afterwards proved GQDs’ efficacy on Parkinson’s disease through cell and mouse model studies. This research was the foundation for BioGraphene establishment.

He received a Ph.D. in Chemistry from Seoul National University and a B.S. in Chemistry from Johns Hopkins University.